Mitoxantrone hydrochloride

盐酸米托蒽醌

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameMitoxantrone hydrochloride
Drug Alias Name盐酸米托恩醌Mitoxantrone packaged EnGeneIC Delivery VehicleMitoxantrone packaged EnGeneIC Dream Vector米拖蒽醌米脱蒽醌 +[22] 
ClassificationSmall molecules
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsSolid tumoursNeuromyelitis OpticaMultiple Sclerosis, Relapsing-Remitting +[24] 
Global Approved IndicationsMultiple Sclerosis, Relapsing-RemittingProstatic Neoplasms, Castration-ResistantBreast Neoplasms +[6] 
Approved Indications in ChinaBreast NeoplasmsLymphomaLeukemia
Original Approved Country/TerritoryJapan
Original Approved Date1987/12/10
Country/TerritoryCzechiaBelgiumUnited States +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesAska Pharmaceutical Co LtdCharite University, Berlin, GermanyChengdu Beite Danuo Pharmaceutical Co Ltd +[4] 
Inactive CompaniesWyeth LlcCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdEmd Serono Inc +[6] 
Active IndicationsNeuromyelitis OpticaBreast NeoplasmsCarcinoma, Hepatocellular +[6] 
Inactive IndicationsSolid tumoursMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive +[18] 

Other Information

ATC CodeL01DB07
Related LinksWikipediaDrugBankKEGG